Diagnosing soft tissue sarcomas among the great number of benign soft tissue lumps and bumps in routine practice is challenging. Soft tissue sarcomas are rare, accounting for only 0.7% of all malignancies estimated to be diagnosed in 2016 in the United States.[@CR1] Also, they often are asymptomatic or cause unspecific signs and symptoms. Therefore, STS patients are at risk of delayed or incorrect diagnosis.[@CR2] Because of these issues, unplanned excisions (UEs) are frequently performed. The proportion of patients referred following UE ranges between 18 and 53.3% of patients treated for STS at a sarcoma centre.[@CR3] ^--^ [@CR5]

Because UEs are usually the result of primary attempts to remove a lesion that is thought to be benign, they carry a high risk of residual tumour.[@CR4],[@CR6] Following UE, decision for or against re-resection, adjuvant radiotherapy (RTX), chemotherapy (CTX), or watchful waiting at the specialist centre is based on surgical and histological reports, resection margin status, and imaging taken prior to UE. Considering that marginal or even intralesional resection margins significantly increase the likelihood for local recurrence (LR), re-resections aiming at removal of residual tumour tissue often are justified.[@CR6]

The combination of primarily inadequate resection, an unavoidable delay from UE to definite surgery, and the peril of residual tumour tissue all suggest that UE patients would do worse compared with initially adequately treated patients. Surprisingly, several study groups reported that UE patients have an identical or even better prognosis than patients who undergo planned surgery.[@CR5] ^--^ [@CR7] It was concluded that patients with large and high-grade tumours at complicated anatomical sites are far more likely to be referred directly to a specialist centre, thus causing a selection bias. According to Lewis et al., however, even adjustment for these influential factors revealed a prognostic advantage for re-resected patients.[@CR6] The present multicentre study was designed to elucidate the baseline characteristics of UE cases, their impact on management at the specialist centre, and their potential influence on patient outcomes.

Methods {#Sec1}
=======

Patients {#Sec2}
--------

We included 728 patients undergoing surgery for STS between 1998 and 2015 at three sarcoma centres (Department of Orthopaedic Surgery, Medical University Graz; Orthopaedic Hospital Gersthof, Vienna; Sarcoma Centre, HELIOS-Klinikum Berlin-Buch). The mean patients' age was 58 years (range 6--96 years; standard deviation (SD): ±16.9 years); 352 were female (48.4%) and 376 male (51.6%).

A standard template was used for data collection at each centre. UEs were defined as unintentionally performed resections of a subsequently histologically verified STS. Original tumour size was ascertained from preoperative MRI and/or medical records or from pathology reports following primary surgery at the specialist centre or index surgery performed elsewhere. Tumour grade was recorded according to the *FNCLCC* system. Staging was done by using the *AJCC Cancer Staging Manual* from 2010. Patients with metastatic disease (*n* = 59) or unknown metastatic status at time of diagnosis (*n* = 11) were excluded from time-to-event analyses, resulting in 658 eligible patients.

All patients were discussed in multidisciplinary team meetings and underwent primary surgery or re-resection following UE at one of the three sarcoma centres. Need for plastic, vascular, or endoprosthetic reconstruction at definite surgery was documented. Neoadjuvant, adjuvant, and palliative treatments (RTX, CTX) were recorded.

Follow-up was performed until July 2016. Time to last follow-up or death was calculated from definite surgery to last known date (most recent clinical appointment, telephone contact, or record in obituary column). The study was approved by the institutional review boards at the respective centres.

Statistical Analysis {#Sec3}
--------------------

Statistical analysis was performed using IBM SPSS statistics version 23.0, Microsoft Excel version 15.19.1 and Stata (Windows version 13.0, Stata Corp., Houston, TX). Continuous variables were summarised as means ± SD, whereas count data were summarised as absolute frequencies with percentages. Associations between two categorical variables, as tumour grade and UE status, were analysed with *χ* ^2^ tests (expected cell counts ≥5) or Fisher's exact tests (expected cell counts \<5). Means between two groups were compared with *t* tests or in case of heteroscedasticity with Wilcoxon's rank-sum tests. Median survival was estimated with the reverse Kaplan--Meier method by Schemper and Smith. The Kaplan--Meier product-limit estimator was used to calculate survivor functions. Cumulative incidences of LR and distant metastasis (DM) were estimated with competing risk estimators according to Marubini and Valsecchi, treating death-from-any-cause as the competing event of interest. Survivor and cumulative-incidence functions were compared between two or more groups with log-rank and Gray's tests, respectively. Uni- and multivariable modelling of time-to-event outcomes was performed with Cox-proportional hazards models for the overall survival (OS) endpoint and Fine & Gray's proportional subdistribution hazards models for the LR and DM endpoints.

A propensity score (PS), defined as the probability of undergoing UE, was estimated for each individual patient according to characteristics at baseline.[@CR8] The PS was calculated with a binary logistic regression model, including the following variables: gender, patient's age, anatomical tumour localisation, histologic subtype, tumour depth, size, and tumour grade. Next, an inverse-probability-of-UE weight (IPUEW) was constructed, defined as 1/PS for patients with prior UE and 1/(1−PS) for directly referred patients. Time-to-event analyses for OS, LR, and DM were then weighted using this IPUEW. Sensitivity analyses used a trimmed IPUEW (i.e., the lowest and highest 5% were removed) that did not materially alter the observed associations.

Results {#Sec4}
=======

Patient characteristics at baseline, tumour-related parameters, definite treatment, and postoperative information are presented in Table [1](#Tab1){ref-type="table"}. The mean tumour size was 8.9 cm (range 0.5--47.0 cm; SD: ±6.3 cm), being significantly smaller in superficial STS than in tumours underneath the fascia (6.1 ± 4.8 cm; 10.2 ± 6.4 cm; *t* test, *p* = 0.005). With 457 cases, most STS were located in the lower limbs (62.8%), mainly the thigh. A total of 276 patients had AJCC stage III tumours (40%), and a further 59 had evidence of metastatic disease at time of diagnosis (8.6%). Table 1Descriptive analysis for all patients and differences depending on prior unplanned excision (UE)Total (*n* = 728)Unplanned excisionMissing*p* value (*χ* ^2^ test)No (*n* = 447)Yes (*n* = 281)Centre A42726216500.484 B986533 C20312083Gender Female3522291230**0.050** Male376218158Tumour location Upper limb14373700**\<0.005** Lower limb457310147 Trunk985048 Other301416Detailed symptoms No symptoms8154271580.308 Pain886028 Increase303202101 Pain + increase967422Tumour size (cm) 0--52288314599**\<0.005** 5--1018112556 \>1022018337Histology Liposarcoma1831265700.270 Myxofibrosarcoma16110061 Leiomyosarcoma764432 Synovial Sarcoma643430 MPNST21129 Fibrosarcoma633 Other21712889Depth Superficial230931376**\<0.005** Deep492352140Grading G11358847380.298 G21387959 G3417267150Staging IA35112438**\<0.005** IB987622 IIA1385088 IIB845925 III27619878 IV594019Primary LN metastasis No69543026590.950 Yes24159Primary distant metastasis No68041226850.071 Yes433211Duration of symptoms (mo) \<631522788175**0.008** \>623813692Amputation No6633992640**0.031** Yes654817Plastic reconstruction No5053451603**\<0.005** Yes220101119Vascular reconstruction No68741926830.215 Yes382711Endoprosthetic devices No6774092683**0.022** Yes483711R-classification R058334523871**0.001** R1675215 R2770Postoperative complications No56134721430.730 Yes1649965Radiotherapy\* No284184100100.119 Yes434256178Adjuvant radiotherapy No3302161140**0.041** Yes398231167Chemotherapy\* No50129220910**0.009** Yes21714968Local recurrence No61838423450.431 Yes1056144Distant metastasis No5493242258**0.019** Yes17111853Statistically significant results are given in bold\* Comprising neoadjuvant, adjuvant, palliative, or combined treatment regimes

The median duration of symptoms before admission was 6 months (range 3 weeks--30 years). In total, 399 patients had noticed a recent increase of the tumour (70.2%), which was painless in 303 cases and associated with pain in 96. An additional 88 patients had experienced pain only (15.5%), whereas 81 reported no symptoms at all (14.3%).

Altogether, 281 STS patients had undergone UE before referral (38.6%), with a similar incidence at each centre (Table [1](#Tab1){ref-type="table"}). The median delay from UE to definite surgery was 7.9 weeks, with 68.7% of patients treated within 12 weeks (*n* = 193).

At the centres, most patients underwent wide (*n* = 492; 67.6%) and compartmental tumour resection (*n* = 85; 11.7%). Limb-salvage surgery was not feasible in 10.7% of primary surgeries (*n* = 48) compared with 6.0% of re-resections (*n* = 17; *p* = 0.031).

A total of 220 patients required plastic reconstructions, as muscular flaps (35.9%) and split-skin grafts (32.3%). These reconstructions were necessary in 42.7% of re-resections (*n* = 119) compared with 22.6% of planned surgeries (*n* *=* 101; *p* \< 0.005). At definite surgery, clear tumour margins (R-Classification; R0) could be achieved in 583 cases (88.7%), microscopically intralesional margins (R1) in 67 cases (10.2%), and macroscopically intralesional margins (R2) in 7 cases (1.1%).[@CR9],[@CR10] Postoperative complications that necessitated revision developed in 164 patients (22.6%; Table [1](#Tab1){ref-type="table"}). The rate of postoperative complications did not significantly differ between UE and non-UE -patients (23.3 vs. 22.1%; *p* = 0.730).

Of 434 patients receiving RTX (60.4%), the vast majority underwent postoperative irradiation of the tumour bed (*n* = 398). Patients who underwent re-resection received adjuvant RTX more often than patients who had planned surgery (59.4 vs. 51.7%; *p* = 0.041).

Altogether, 30.2% of patients (*n* = 217) were administered CTX in a neoadjuvant (*n* = 45), adjuvant (*n* = 70), palliative (*n* = 33), or combined treatment regimen (*n* = 69). After a median follow-up of 5.5 years (25th--75th percentile 3.0--8.4 years), 82 patients were alive with disease (11.3%) and 399 had no evidence of disease (54.8%); 129 patients died of STS (17.7%) and 73 died due to other causes (10%). UE patients accounted for 31% (*n* = 40) and non-UE patients for 69.0% (*n* = 89) of cancer-related deaths.

Of 658 patients with localised disease at time of diagnosis, 92 subsequently developed LR (14.0%), whereas 137 patients (20.8%) developed DM. The 5- and 10-year OS rates for all patients were 77.7 and 63.8%, respectively. 5 and 10-year risks of LR were estimated at 12.8 and 20.4% and corresponding risks of DM at 22.3 and 25.0% (Fig. [1](#Fig1){ref-type="fig"}). Tumour size (*p* = 0.004), grade (*p* = 0.013), stage (*p* \< 0.005), histological subtype (*p* = 0.007), symptoms lasting for less than 6 months (*p* \< 0.005), and use of CTX (*p* \< 0.005) were significant predictors of survival using univariable analysis (Table [2](#Tab2){ref-type="table"}). UE patients undergoing definite surgery later than 12 weeks had a 113% higher relative risk for LR (subdistribution hazard ratio (SHR): 2.135; 95% confidence interval (CI) 1.108--4.112; *p* = 0.023) and a 186% higher relative risk of DM (SHR: 2.863; 95% CI 1.483--5.537; *p* = 0.002) than those treated earlier than 12 weeks.Fig. 1Overall survival (OS) and cumulative incidences of local recurrence (LR) as well as distant metastasis (DM) calculated for patients with localised disease at time of diagnosis (*n* = 658) Table 2Univariable Cox-regression analysis regarding overall survival for patients without primary metastasis at time of diagnosisHR95% CI*p* valueLowerUpperGender (*n* = 658) Female10.794 Male1.0430.7621.427Tumour location (*n* = 658) Upper limb1 Lower limb0.7880.3631.7110.547 Trunk0.7740.3761.5920.486 Other0.7120.3011.6830.439Tumour size (cm) (*n* = 568) 0--51 5--101.9531.2503.051**0.003** \>101.9531.2762.987**0.002**Histology (*n* = 652) FibrosarcomaNENENENE Liposarcoma1 Myxofibrosarcoma2.0811.2253.536**0.007** Leiomyosarcoma3.5101.9666.266**\<0.005** Synovial sarcoma2.9091.5485.466**0.001** MPNST3.4111.5227.648**0.003** Other3.2121.9515.289**\<0.005**Depth (*n* = 652) Superficial10.762 Deep1.0550.7471.490Grading (*n* = 625) G11 G22.5261.2185.239**0.013** G35.4512.85410.411**\<0.005**Staging (*n* = 623) IA / IB1 IIA / IIB2.8461.4345.648**0.003** III6.1703.21411.843**\<0.005**Unplanned excision (*n* = 658) No1**0.027** Yes0.6890.4940.961Duration of symptoms (mo) (*n* = 492) \<61**\<0.005** \>60.5380.3690.782Postoperative complications (*n* = 654) No10.870 Yes1.0300.7181.478Radiotherapy\* (*n* = 651) No10.400 Yes1.1520.8291.600Adjuvant radiotherapy (*n* = 657) No10.495 Yes1.1180.8121.539Chemotherapy\* (*n* = 651) No1**\<0.005** Yes1.8931.3782.601Statistically significant results are given in bold*NE* nonestimable: hazard ratio could not be estimated for the fibrosarcoma-subgroup (*n* = 6, no deaths during follow-up period)\* Comprising neoadjuvant, adjuvant, palliative, or combined treatment regimes

Univariable analysis revealed that UEs with consecutive re-resection were significantly associated with improved OS compared with primary surgeries (hazard ratio (HR): 0.689; 95% CI 0.494--0.961; *p* = 0.027; Fig. [2](#Fig2){ref-type="fig"}a). At 5 and 10 years, 82.3 and 67.5% of patients with underwent resection were alive compared with 74.8 and 61.4% of patients after planned surgery. UE patients developed DM less frequently than patients with planned surgery (*p* = 0.002; Fig. [2](#Fig2){ref-type="fig"}b), whereas LR-free survival rates were similar for both groups (*p* = 0.359; Fig. [2](#Fig2){ref-type="fig"}c).Fig. 2Comparison between patients with prior unplanned excision (UE) and patients undergoing planned surgery (no UE). Juxtaposition of results obtained by univariable analysis and IPUEW-weighted analysis in terms of overall survival (2**a** vs. 2**d**), risk of local recurrence (2**c** vs. 2**f**; LR analysis using a 5% trimmed IPUEW), and risk of distant metastasis (2**b** vs. 2**e**)

In multivariable analysis, tumour size and grade were confirmed as independent prognostic factors for OS, whereas the favourable "effect" of UE did not prevail after adjustment for selected covariates (HR: 0.737; 95% CI 0.501--1.085; *p* = 0.122; Table [3](#Tab3){ref-type="table"}).Table 3Multivariable Cox-regression analysis concerning overall survival for patients without primary metastasis at time of diagnosis (*n* = 543)HR95% CI*p* valueLower limitUpper limitTumour size (cm) 0--51 5--101.8641.1682.975**0.009** \>102.3091.4383.707**0.001**Depth Superficial10.266 Deep0.7930.5271.193Grading G11 G22.8091.3375.902**0.006** G35.9653.06611.532**\<0.005**Unplanned excision No10.122 Yes0.7370.5011.085Statistically significant results are given in bold

However, some significant differences at baseline between patients undergoing UE and those with planned surgery were observed (Table [1](#Tab1){ref-type="table"}). Tumours undergoing UE were significantly smaller (*p* \< 0.005), were preferably located superficially (*p* \< 0.005), and more often had been noticed by patients some time ago (*p* = 0.008). Male patients were more likely to have their tumours excised inadvertently compared with females (*p* = 0.05). UE patients were younger on average than directly referred ones (56.5 vs. 59.2 years; *p* = 0.036). Because most of the abovementioned parameters are well-established prognostic factors, they potentially have a greater influence on survival than UE itself.

To adjust for these confounding factors, IPUEW analysis was performed as described in the "[Methods](#Sec1){ref-type="sec"}" section. The odds of being in the UE group differed according to whether tumours were superficially located (odds ratio (OR) for superficial location to being a non-UE patient: 0.29, *p* \< 0.0001). After adjusting for the PS, this difference vanished (OR: 1.04, *p* = 0.875), thus supporting the concept that this PS adequately controlled for imbalances between UE- and non-UE patients. After weighting for the IPUEW score, UEs with subsequent re-resection were not significantly associated with an improved survival any more (HR: 0.85; 95% CI 0.56--1.30; *p* = 0.459; Fig. [2](#Fig2){ref-type="fig"}d), in conformity with the multivariable analysis. Differences in terms of DM-free survival were likewise lost following IPUEW score weighting (*p* = 0.405; Fig. [2](#Fig2){ref-type="fig"}e).

Discussion {#Sec5}
==========

In this retrospective, multicentre study, we analysed the association between unplanned excision, subsequent therapy, local recurrence, distant metastasis, and overall survival in 728 patients with STS. In univariable analysis, patients with prior UE had significantly better overall survival than patients with primary surgery at the tumour centre. However, favourable prognostic factors, such as small, low-grade tumours and superficial location, were more common in patients with UE. These data strongly support the concept that UEs per se, given that they are followed by appropriate definite surgery at a tertiary centre, have no major prognostic impact in patients with STS.

Patients referred following UEs are a widely known phenomenon, accounting for up to 53.3% of all STS patients treated at tumour centres.[@CR3] ^--^ [@CR5] In our cohort, 38.6% of patients treated at one of the three centres had undergone UE outwards. The rates that we found are comparable to the 37% reported by Lewis et al. and 34.8% observed by Koulaxouzidis et al.[@CR6],[@CR11]

A combination of various factors tempts physicians to excise a soft tissue tumour. STS from our cohort undergoing UE had been small and were preferably located clearly visible in the subcutis. Similar observations have been made by other investigators.[@CR3],[@CR6],[@CR12] Interestingly, the quality of symptoms did not significantly alter the rate of inadvertent resections, albeit patients reporting a long history of complaints were more likely to undergo UE. Moreover, we observed a difference for gender and age; significantly more males and younger patients underwent UE.

Due to smaller and more often superficially located tumours, UE patients were less likely to undergo amputation at definite surgery compared with directly referred patients. However, in 42.7% of re-resections after UE, muscular flaps and split-skin grafts were required, whereas plastic reconstructions became necessary in 22.6% of primary surgeries only. Similar disparities have been reported by Potter et al. In their cohort, however, only 5% of planned surgeries but 30% of re-resections necessitated plastic-reconstructive soft tissue coverage.[@CR13]

Because of soft tissue damage, unclear resection margins or frank residual tumour following UE, radical therapeutic approaches are chosen during re-resection in relation to the original tumour size. Whether irradiation following re-resection reduces rate of LR has been discussed controversially. Most authors have concluded that RTX should be administered deliberately, based on tumour extent, postoperative margin status, and histology.[@CR13] ^--^ [@CR15] At least in high-grade STS \>5 cm with a deep location, the risk for LR seems to be reduced by RTX.[@CR14] The small average-tumour size notwithstanding, significantly more of our UE patients (59.4%) underwent postoperative irradiation compared with patients who had planned surgery (51.7%). These findings are consistent with previous observations.[@CR13]

Despite more often requiring plastic reconstructions and receiving adjuvant RTX, UE patients did not develop postoperative complications more frequently than non-UE patients in our cohort. There is no doubt, however, that many UE-patients could be protected from disproportionate treatment strategies in relation to the underlying pathology if they would be referred directly.

Preoperative RTX has proven effective in the management of distinct STS subtypes.[@CR16] However, administration of RTX before definite surgery may not be suitable for UE patients, due to an elevated risk of perioperative complications.[@CR17]

As a result of more complex treatment approaches, UE are associated with considerable financial consequences. According to Alamanda et al., professional costs (i.e., charges billed by surgeons) significantly increased in re-resections compared with primary surgeries.[@CR18] Even after adjustment for influential parameters, such as tumour grade, site, size, and the fitness of patients before surgery, re-excisions were associated with a 33% increase in professional charges.[@CR18]

Patients subjected to definite surgery at one of the three tumour centres later than 12 weeks following UE had a higher risk for LR and DM compared with those undergoing re-resection shortly after inadvertent resection. Comparable results have been reported by Funovics et al. analysing 310 STS patients with a history of prior UE.[@CR19]

The OS rate of our patients with localised disease at time of diagnosis was 77.7% at 5 years and 63.8% at 10 years. In line with literature, large tumour size and high tumour grade were independent negative prognostic factors.[@CR15] Several studies have reported an elevated risk for LR despite wide re-resection for prior inadvertently excised STS compared with patients who underwent planned surgery, whereas others did not observe any difference.[@CR5],[@CR6],[@CR13],[@CR20],[@CR21]

We found that patients who underwent UE with consecutive re-resection had a significantly better prognosis in the univariable analysis (*p* = 0.027). Moreover, they seemed to have a lower risk of developing DM, whereas LR-free survival was comparable to patients treated adequately from the beginning.

After adjusting for the IPUEW score, however, the differences in DM-free survival (*p* = 0.405) and OS (*p* = 0.459) between patients with and without prior UE disappeared. Fiore et al. reported the same conjuncture in a cohort of 597 patients with STS, of whom 53.3% had been referred after UE.[@CR5] They used a multivariate analysis, including tumour size, depth, grade, and histological subtype, to estimate the effect of UE on OS.[@CR5] In this study, we also applied multivariable analysis but additionally used IPUEW score-weighting. Both the multivariable adjustment and the IPUEW score-weighted analysis supported our conclusions.

A limitation of this study is its retrospective design, entailing dependency on exhaustive patient history and detailed medical records during follow-up. Additionally, our cohort comprises likewise patients with STS of the extremities, trunk, head, and neck. Moreover, it hardly is possible to assess the impact of potential overtreatment following UE on the patient's prognosis in a retrospective setting and results apply only to UE patients who have actually been referred to a tertiary centre. Thus, UE patients may have a significantly worse prognosis in case treatment based on the same parameters used for directly referred patients (e.g., tumour size, depth, grade).

Conclusions {#Sec6}
===========

Our study does not support prior findings that unplanned excisions improve patient outcomes. There also is no evidence that inadvertent resections might be harmful to prognosis. Unplanned excisions have, however, an influence on the extent of subsequent therapeutic procedures. More radical surgical approaches requiring plastic reconstruction and the increased need for postoperative radiotherapy compromise the medical condition of patients with prior unplanned excisions. For that reason, they must be avoided by all means.
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